The medication doesn't replace condoms, PrEP, or regular testing.
Em um passo que redefine os contornos da saúde sexual pública, o Brasil incorporou ao SUS o DoxiPEP — o uso da doxiciclina após exposição sexual de risco como escudo contra sífilis e clamídia. A decisão, publicada em março de 2026, reconhece que a prevenção não é um ato único, mas uma arquitetura de camadas, e que populações historicamente vulneráveis merecem ferramentas à altura de sua exposição. Nos próximos seis meses, o país testará não apenas a eficácia de um antibiótico, mas a capacidade do Estado de traduzir política em cuidado real.
- As taxas de sífilis e clamídia seguem elevadas entre homens que fazem sexo com homens, mulheres trans e pessoas vivendo com HIV — grupos que agora ganham acesso formal a uma nova camada de proteção.
- O DoxiPEP reduz o risco de sífilis em até 88% e de clamídia em cerca de 65% quando tomado em até 72 horas após a exposição, números que reposicionam o antibiótico como ferramenta de prevenção, não apenas de tratamento.
- Estados e municípios têm até 180 dias para integrar o medicamento à rede pública, um prazo que esconde o desafio real: alcançar as pessoas certas, nos lugares certos, sem burocracia que esvazie a promessa.
- Especialistas alertam que o uso frequente de doxiciclina pode acelerar a resistência bacteriana, tornando a supervisão médica e o uso direcionado condições inegociáveis para o sucesso da estratégia.
- A medida não substitui preservativos, PrEP, vacinas ou testagem regular — ela se soma a eles, ampliando o repertório de prevenção sem dispensar nenhuma das ferramentas já consolidadas.
O Ministério da Saúde do Brasil autorizou, em 11 de março de 2026, a incorporação do DoxiPEP ao Sistema Único de Saúde. A estratégia consiste na ingestão de 200 miligramas de doxiciclina até 72 horas após uma relação sexual de risco, com o objetivo de impedir que infecções bacterianas se estabeleçam no organismo. Estudos clínicos indicam reduções de 77 a 88% no risco de sífilis, cerca de 65% para clamídia e aproximadamente 54% para gonorreia.
O acesso será direcionado a populações com maior vulnerabilidade epidemiológica: homens que fazem sexo com homens, homens gays e bissexuais, mulheres trans, e pessoas vivendo com HIV ou sem diagnóstico da infecção. Estados e municípios têm até 180 dias para disponibilizar o medicamento em clínicas e hospitais públicos.
Especialistas em doenças infecciosas, como o infectologista Hilton Luís, ressaltam que o DoxiPEP não é uma solução isolada. O antibiótico não protege contra todas as ISTs, não previne gravidez e não substitui preservativos, PrEP, vacinas ou testagem periódica. Pesquisas sobre programas semelhantes sugerem que os usuários não alteram significativamente seu comportamento sexual, mas relatam maior sensação de segurança.
A resistência bacteriana é o principal ponto de atenção: o uso frequente de doxiciclina pode favorecer a evolução de bactérias resistentes ao medicamento, comprometendo sua eficácia a longo prazo. Por isso, diretrizes internacionais recomendam uso supervisionado e restrito a populações específicas. O sucesso da medida dependerá tanto da capacidade logística do SUS quanto da habilidade de alcançar, de fato, quem mais precisa dessa nova camada de proteção.
Brazil's Health Ministry has authorized a new tool in the fight against sexually transmitted infections: doxycycline taken as a preventive measure after unprotected sex. The decision, published in the official government gazette on Wednesday, March 11, will be incorporated into the public health system, known as SUS. Local and state health authorities have up to 180 days to begin offering the medication through public clinics and hospitals.
The strategy, called DoxiPEP, works by having a person take 200 milligrams of doxycycline within 72 hours of a sexual encounter considered high-risk—typically unprotected intercourse. The antibiotic aims to prevent bacterial sexually transmitted infections from establishing themselves in the body. Clinical research suggests the approach is effective: studies show it can reduce the risk of syphilis by between 77 and 88 percent, lower the chance of chlamydia infection by roughly 65 percent, and provide about 54 percent protection against gonorrhea.
The Health Ministry's technical committee determined that DoxiPEP should be available to groups with higher vulnerability to these infections. Eligible populations include men who have sex with men, gay and bisexual men, and transgender women. The medication can be used by people living with HIV as well as those without an HIV diagnosis. This targeted approach reflects epidemiological data showing where infection rates are highest and where prevention efforts should be concentrated.
But infectious disease specialists are careful to frame what DoxiPEP is and is not. Hilton Luís, an infectologist quoted in the Health Ministry's analysis, emphasizes that the antibiotic must be part of a broader prevention strategy. "This doesn't mean anything goes," he explained. "The medication doesn't protect against all sexually transmitted infections, doesn't prevent pregnancy, and doesn't replace condoms, PrEP for HIV, vaccines, or regular testing." Research on similar programs suggests that people using DoxiPEP don't typically change their sexual behavior significantly, but they do report feeling safer.
Another concern weighing on public health officials is the specter of antibiotic resistance. When antibiotics are used frequently, bacteria can evolve to survive them—a phenomenon that threatens the effectiveness of these drugs across medicine. Luís noted that repeated use of doxycycline could allow some bacteria to develop resistance to the medication, a genuine public health risk. For this reason, international guidelines recommend that DoxiPEP be used only by specific populations and under the supervision of healthcare providers, not as a casual, over-the-counter option.
The two infections DoxiPEP targets are common and consequential. Syphilis, caused by the bacterium Treponema pallidum, often begins with a painless sore in the genital area, anus, or mouth. Left untreated, it can progress to damage the heart and nervous system. Chlamydia, caused by Chlamydia trachomatis, frequently produces no symptoms at all, which is part of what makes it dangerous—people can transmit it without knowing they're infected. When symptoms do appear, they include genital discharge, pain during urination, and pelvic pain. Over time, untreated chlamydia can lead to infertility and pelvic inflammatory disease.
The rollout of DoxiPEP represents a shift in how Brazil approaches sexual health prevention. Rather than relying solely on condoms, testing, and treatment after diagnosis, the public health system is now offering a pharmaceutical intervention designed to stop infection before it takes hold. The next six months will determine how effectively states and municipalities can integrate this new tool into existing health infrastructure and how well they can reach the populations most likely to benefit from it.
Citas Notables
This doesn't mean anything goes. The medication doesn't protect against all sexually transmitted infections, doesn't prevent pregnancy, and doesn't replace condoms, PrEP for HIV, vaccines, or regular testing.— Hilton Luís, infectologist
Using antibiotics repeatedly can cause bacteria to develop resistance to the medication, a genuine public health risk.— Hilton Luís, infectologist
La Conversación del Hearth Otra perspectiva de la historia
Why did the Health Ministry decide to authorize this particular drug for this particular use right now?
The decision is based on clinical evidence showing that doxycycline, taken quickly after exposure, genuinely prevents some bacterial infections from establishing themselves. But it's also a response to epidemiology—syphilis and chlamydia rates have been rising in specific populations, and the ministry wanted to offer another option beyond condoms and testing.
Who exactly can access it?
Men who have sex with men, gay and bisexual men, and transgender women. The ministry identified these groups as having higher infection rates and therefore higher need. People with HIV can use it too, as can people without HIV.
Does it work?
For syphilis, yes—77 to 88 percent effective. For chlamydia, about 65 percent. Gonorrhea is lower, around 54 percent. But those numbers matter only if someone takes it within 72 hours of exposure.
So people will just stop using condoms?
That's what experts worried about, but research from other countries suggests it doesn't happen. People feel safer, but they don't dramatically change their behavior. The real concern is something else: using antibiotics this way, repeatedly, could create resistant bacteria.
Resistant to what?
To doxycycline itself. If bacteria encounter the drug often enough, they evolve to survive it. Then the drug stops working for anyone—not just for this prevention strategy, but for treating actual infections too.
So this could backfire?
Only if it's misused—if it becomes casual or widespread without medical oversight. That's why guidelines say it should be targeted, supervised, and part of a larger prevention strategy that still includes condoms and regular testing.